A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

523

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Solid Tumors
Colorectal Cancer
Gastric Cancer
Gastroesophageal-junction Cancer
NSCLC
HNSCC
Head and Neck Squamous Cell Carcinoma
Esophageal Cancer

Interventions

DRUG: MCLA-158
COMBINATION_PRODUCT: MCLA-158 + Pembrolizumab
COMBINATION_PRODUCT: MCLA-158 + FOLFIRI
COMBINATION_PRODUCT: MCLA-158 + FOLFOX

Sponsor

Merus B.V.